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4 Abstract	  A	  better	  understanding	  of	  mechanisms	   that	   regulate	   cellular	   lifespan	   is	  needed	   to	  exploit	   the	   balance	   between	   senescence	   in	   normal	   cells	   and	   uncontrolled	  proliferation	   in	   cancer	   cells.	  We	   show	   that	   low	  oxygen	   and	   supplementation	  with	  FGF2	   significantly	   extends	   cellular	   lifespan.	   Cells	   decrease	   expression	   of	   tumor	  suppressor	  p53	  and	  p53	  is	  downregulated	  further	  in	  late-­‐passage	  cells.	  Lower	  levels	  of	  p53	  protein	  accompany	  lower	  levels	  of	  transcription.	  	  
5 Introduction	  
5.1 The	  Cell	  Cycle	  and	  Its	  Regulation	  	  All	  mammalian	  cells	  reproduce	  by	  progressing	  through	  a	  specific	  series	  of	  events	  to	  generate	   copies	   of	   their	   DNA	   and	   organelles	   prior	   to	   dividing	   into	   daughter	   cells	  that	  contain	  a	   full	   set	  of	  DNA	  and	   the	  complete	  organelle	  repertoire.	  This	  process,	  which	  regulates	   internal	  duplication	  and	   the	  subsequent	  division,	   is	  called	   the	  cell	  cycle.	   Each	   defined	   event	   in	  mitosis	   can	   be	   categorized	   by	   the	   portion	   of	   the	   cell	  cycle	  during	  which	  it	  occurs,	  and	  the	  cycle	  can	  be	  broken	  into	  four	  distinct	  phases:	  G1,	   S,	   G2,	   and	   M,	   and	   one	   additional	   possible	   phase,	   G0,	   that	   the	   cell	   can	   enter	   if	  necessary	  (Cooper,	  2000).	  G1	  and	  G2	  are	  growth	  phases	   in	  which	  the	  cell	  monitors	  the	  external	  environment	  and	  confirms	  that	  the	  cell	  is	  ready	  to	  proceed	  to	  the	  next	  phase.	   G1	   is	   the	   interval	   between	   cell	   division	   and	   S	   phase,	   during	  which	   the	   cell	  grows.	   G2	   follows	   S	   phase	   and	   is	   another	   period	   of	   cellular	   growth.	   The	   cell	   also	  synthesizes	  essential	  proteins	  for	  mitosis	  during	  G2.	  S	  phase	  refers	  to	  the	  synthesis	  of	  DNA,	  because	  the	  cell	  replicates	  its	  genome	  during	  this	  phase.	  The	  actual	  division	  of	   the	   cell	   occurs	   during	   mitosis,	   or	   M	   phase,	   which	   follows	   G2.	   M	   phase	   can	   be	  broken	   down	   into	   five	   more	   descriptive	   phases:	   prophase,	   metaphase,	   anaphase,	  telophase,	   and	   cytokinesis.	   During	   the	   first	   four	   of	   these	   phases	   nuclear	   division	  occurs,	   in	  which	  chromosomes	  (condensed	  DNA)	  align	  with	  their	  duplicates	  at	   the	  center	  of	  the	  cell	  and	  are	  segregated	  at	  either	  pole	  of	  the	  undivided	  cell.	  Once	  all	  has	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been	   segregated	   appropriately,	   the	   cell	   begins	   cytokinesis	   and	   two	   daughter	   cells	  are	  formed,	  each	  with	  a	  complete	  genome	  (Alberts	  et	  al.,	  2008).	  	  	  
	  
Figure	  5.1	  Regulation	  at	  cell	  cycle	  checkpoints	  controls	  how	  a	  cell	  progresses	  
through	  the	  cell	  cycle.	  	  	  Eukaryotic	  cells	  have	  a	  complex	  system	  of	  proteins	  that	  controls	  progression	  of	  the	  cell	   cycle	  and	  establishes	  checkpoints	  prior	   to	  moving	   from	  one	  phase	   to	  another.	  The	  cell-­‐cycle	  control	  system	  ensures	  that	  the	  cell’s	  DNA	  has	  been	  fully	  replicated,	  its	  mistakes	  corrected,	  and	   that	  each	  daughter	  cell	   is	   complete.	   If	   this	  biochemical	  checkpoint	   system	   fails,	   cells	   can	   continue	   dividing	   in	   the	   presence	   of	   replication	  errors	  or	  unrepaired	  mutations,	  potentially	  resulting	  in	  cancer	  (Alberts	  et	  al.,	  2008).	  One	  of	  the	  most	  important	  checkpoints	  in	  the	  eukaryotic	  cell	  cycle	  is	  the	  “restriction	  point,”	  which	   occurs	   late	   in	   G1.	   It	   functions	   as	   a	   decision	   point	   that	   regulates	   the	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cell’s	  passage	  into	  S	  phase	  and	  the	  rest	  of	  the	  cell	  cycle.	  A	  eukaryotic	  cell’s	  passage	  through	  the	  restriction	  point	  is	  regulated	  predominantly	  by	  the	  presence	  of	  specific	  growth	  factors.	  If	  there	  is	  an	  absence	  of	  the	  appropriate	  growth	  factors,	  the	  cell	  will	  enter	   a	   quiescent	   stage,	   called	   G0,	   during	  which	   it	   is	   still	  metabolically	   active	   but	  does	   not	   grow.	  A	   cell	   can	   escape	  G0	   if	   the	   necessary	   growth	   factors	   are	   provided.	  Eukaryotic	  cells	  must	  also	  pass	  checkpoints	  throughout	  the	  cell	  cycle	  that	  monitor	  DNA	  for	  damage.	  If	  damaged	  DNA	  is	  detected,	  the	  cell	  can	  be	  arrested	  during	  G1	  or	  G2.	  A	  protein	  called	  p53	  regulates	  arrest	  at	  the	  G1	  DNA	  damage	  checkpoint.	  Damaged	  DNA,	  as	  well	  as	  many	  other	  cellular	  stresses,	  activates	  p53	  and	  causes	  it	  to	  initiate	  a	  cascade	   of	   events	   that	   halt	   the	   cell’s	   progression	   through	   the	   cell	   cycle	   until	   the	  damaged	  DNA	  can	  be	  repaired	  (Cooper,	  2000).	  	  	  If	   DNA	   damage	   is	   sensed	   during	   G1,	   ATM	   (ataxia	   telangiectasia,	   mutated;	   a	  serine/threonine	  protein	  kinase)	  phosphorylates	  several	   target	  proteins,	   including	  p53	   and	   Chk2,	  which	   leads	   to	   two	   signal	   transduction	   pathways.	   One	   pathway	   is	  responsible	   for	  halting	   the	   cell	   cycle,	   and	   the	  other	   is	   responsible	   for	  maintaining	  the	   cell’s	   halted	   state	   (Bartek	   and	   Lukas,	   2001).	  When	  Chk2	   is	   phosphorylated,	   it	  inactivates	  CDC25A	  by	  phosphorylation.	  Phosphorylation	  of	  CDC25A	  causes	  it	  to	  be	  excluded	   from	   the	   nucleus	   and	   degraded	   by	   ubiquitin-­‐mediated	   proteasomal	  degradation	  (Molinari	  et	  al.,	  2000;	  Falck	  et	  al.,	  2001).	  This	  causes	  G1	  cell-­‐cycle	  arrest,	  because	   if	   there	   is	   a	   lack	   of	   its	   target,	   CDC25A,	   inactive	   Cdk2	   accumulates	   and	   it	  cannot	   phosphorylate	   the	   targets	   necessary	   for	   the	   cell	   to	   progress	   to	   the	   next	  phase.	   This	   form	   of	   cell	   cycle	   arrest	   signaling	   is	   called	   the	   ATM-­‐Chk2-­‐CDC25	  pathway.	   UV	   damage-­‐induced	   cell	   cycle	   arrest	   is	   signaled	   through	   the	   ATR-­‐Chk1-­‐CDC25	  pathway	  (Sancar	  et	  al.,	  2004).	  In	  this	  pathway,	  ATR	  (ataxia	  telangiectasia	  and	  Rad3	  related)	  or	  a	  similar	  protein	  kinase	  senses	  DNA	  damage	  and	  activates	  Chk1	  by	  phosphorylation.	   Phosphorylated	   Chk1	   can	   then	   phosphorylate	   CDC25A	   and	  therefore	  cause	  cell	  cycle	  arrest	  (Sancar	  et	  al.,	  2004).	  p53	  maintains	  G1/S	  cell	  cycle	  arrest	   after	   phosphorylation	   of	   Ser15	   directly	   and	   Ser20	   indirectly	   through	  activation	  of	  Chk1	  or	  Chk2	  by	  ATM	  or	  ATR	  (Banin	  et	  al.,	  1998;	  Canman	  et	  al.,	  1998;	  Kastan	   and	   Lim,	   2000;	   Ryan	   et	   al.,	   2001;	   Chehab	   et	   al.,	   1999).	   The	   export	   of	   p53	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from	  the	  nucleus	  for	  degradation	  is	  inhibited	  by	  phosphorylation.	  Therefore,	  during	  the	   maintenance	   of	   cell	   cycle	   arrest,	   p53	   accumulates,	   leading	   to	   increased	  activation	  of	  its	  targets,	  including	  p21,	  a	  cell	  cycle	  inhibitor	  (Zhang	  and	  Xiong,	  2001;	  Harper	  et	  al.,	  1993).	  	  	  	  The	   activation	   of	   either	   of	   the	   ATM-­‐Chk2-­‐CDC25	   or	   ATR-­‐Chk1-­‐CDC25	   signal	  transduction	  pathways	  can	  initiate	  the	  halt	  of	  the	  cell	  cycle	  as	  DNA	  damage	  occurs	  during	  G2	   (Zhao	  and	  Piwnica-­‐Worms,	  2001;	  Xu	  et	  al.,	  2002;	  Brown	  and	  Baltimore,	  2003).	   The	   alternate	   pathway	   to	   the	   initial	   pathway	   employed	   is	   responsible	   for	  maintaining	   cell	   cycle	   arrest	   following	   the	   initial	   signaling	   by	   the	   appropriate	  pathway	   for	   the	   type	  of	  DNA	  damage	  (Abraham,	  2001;	  Xu	  et	  al.,	  2002;	  Brown	  and	  Baltimore,	  2003).	  	  Additionally,	  progression	  of	  the	  cell	  cycle	  is	  regulated	  by	  a	  family	  of	  proteins	  called	  cell	  division	  cycle	  (CDC)	  proteins.	  This	  family	  includes	  many	  classes,	  of	  which	  some	  are	   cyclins,	   cyclin-­‐dependent	   kinases	   (CDK),	   mitogen-­‐activated	   kinases,	   and	  phosphoprotein	   phosphatases	   (Nurse,	   et	   al.,	   1998).	   Cyclins	   have	   no	   enzymatic	  activity	   as	   independent	   proteins.	   They	   instead	   function	   by	   binding	   and	   activating	  CDKs.	   In	   order	   for	   CDKs	   to	   become	   enzymatically	   active,	   they	   must	   also	   be	   in	   a	  specified	   phosphorylation	   state.	   The	   specific	   pattern	   of	   phosphorylated	   and	  dephosphorylated	  residues	  determines	  the	  activity	  of	   the	  CDK.	  CDKs	  rely	  on	  other	  kinases	   and	   phosphatases	   to	   achieve	   appropriate	   phosphorylation.	   CDKs	   act	   by	  transferring	   phosphate	   groups	   from	  ATP	   to	   specific	   locations	   on	   their	   substrates.	  Cells	  rely	  on	   the	  appropriate	  phosphorylation	  of	  cyclin-­‐CDK	  complex	  substrates	  at	  specific	  time	  points	   in	  the	  cell	  cycle	  to	  progress.	  Animals	  have	  varying	  numbers	  of	  CDKs,	   though	  vertebrates	  have	   four,	  CDK1,	  CDK2,	  CDK4,	  and	  CDK	  6.	  The	  ability	  of	  CDKs	  to	  target	  multiple	  substrates	  comes	  from	  a	  variety	  of	  phosphorylation	  states	  and	  the	  binding	  of	  different	  cyclins.	  Each	  cyclin	  acts	  during	  a	  specific	  stage	  in	  the	  cell	  cycle	   and	   binds	   a	   single	   CDK.	   While	   CDK	   levels	   are	   kept	   relatively	   constant	  throughout	  the	  cell	  cycle,	  cyclin	   levels	  are	  modulated	  according	  to	  cell	  cycle	  phase	  by	  varying	  their	  manufacture	  and	  degradation	  (O’Connor	  et	  al.,	  2010).	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5.2 Growth	  Factors	  and	  the	  Cell	  Cycle	  	  Fibroblast	  growth	  factors	  (FGFs)	  are	  a	  family	  of	  mitogens	  that	  consists	  of	  23	  known	  members,	   and	   several	   splice	   variants,	   that	   have	   five	   known	   associated	   receptors	  (FGFRs).	   Mitogens	   are	   chemical	   substances	   that	   promote	   progression	   of	   the	   cell	  cycle,	  which	  are	  expressed	  in	  many	  tissues	  and	  cell	  types	  (Shaulian	  et	  al.,	  1997).	  FGF	  activity	  is	  regulated	  by	  tissue-­‐specific	  heparin-­‐sulfate	  proteoglycans	  (HSPGs).	  HSPGs	  can	  either	  activate	  or	   inactivate	  FGFRs	  by	  selective	  phosphorylation	  to	  modulate	  a	  cell’s	  response	  to	  FGFs	  (Zhang,	  et	  al.,	  2006).	  Cellular	  responses	  to	  FGF	  signaling	  vary	  greatly	   and	   depend	   on	   the	   external	   environment,	   interactions	   with	   other	   growth	  factors,	  and	  the	  differentiation	  status	  of	  the	  cell	  (Coutu	  and	  Galipeau,	  2011).	  	  	  FGFs	  have	  been	  shown	  to	  play	  an	  essential	  role	  in	  embryonic	  development	  and	  are	  regulators	  of	  stem	  cell	  self-­‐renewal	  and	  senescence	  (Coutu	  and	  Galipeau,	  2011).	  It	  is	  believed	   that	   FGFs	   helps	   to	   maintain	   a	   balance	   between	   somatic	   stem	   cell	  progenitor	  pools	  and	  cells	  entering	  differentiation	  (Kassem	  and	  Marie,	  2011).	  One	  member	  of	  the	  FGF	  family	  in	  particular,	  FGF-­‐2,	  has	  been	  shown	  to	  contribute	  to	  the	  maintenance	   and	   self-­‐renewal	   of	   pluripotency	   in	   human	   embryonic	   stem	   cells	  (hESCs).	   In	  differentiated	  cells,	  FGFs	  affect	   cell	  proliferation,	  differentiation	  status,	  and	  migration.	  Evidence	  presented	  in	  Coutu	  and	  Galipeau’s	  review	  (2011)	  suggests	  that	  FGF	  acts	  in	  a	  permissive	  role	  to	  stimulate	  differentiation	  in	  committed	  cells	  by	  mediating	  cellular	  responses	  to	  other	  signaling	  molecules.	  FGFs	  appear	  to	  keep	  cells	  from	  senescing	  via	  extension	  of	  proliferative	  cellular	  lifespan.	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Figure	  5.2	  Interactions	  between	  HSPG,	  FGF,	  and	  FGFR	  induce	  signal	  cascade	  
within	  the	  cell.	  	  
5.3 Senescence	  	  Cellular	   senescence	   refers	   to	   the	   irreversible	   arrest	   of	   the	   cell	   cycle	   at	   G1,	   during	  which	   cells	   become	   resistant	   and	   unresponsive	   to	   growth	   factor	   stimulation	  (Nakagawa	   and	   Opitz,	   2007).	   Cells	   can	   typically	   undergo	   a	   limited	   number	   of	  population	   doublings	   before	   they	   enter	   senescence.	   	   This	   limited	   number	   of	  population	   doublings	   is	   termed	   the	   Hayflick	   limit.	   Most	   somatic	   human	   cells	   are	  capable	   of	   about	   40	   to	   60	   population	   doublings	   in	   vitro	   before	   they	   senesce	  (Hayflick	   and	   Moorhead,	   1961).	   Stem	   cells	   and	   cancer	   cells	   do	   not	   have	   typical	  Hayflick	   limits.	  Both	   types	  of	   cells	   can	  divide	   indefinitely,	   though	   stem	  cells	  do	   so	  while	   maintaining	   stable	   karyotype,	   while	   cancer	   cells	   have	   escaped	   normal	   cell	  cycle	  regulation	  and	  can	  produce	  cells	  with	  increasingly	  damaged	  genomes.	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The	   causes	   of	   senescence	   are	   often	   debated.	   It	   has	   yet	   to	   be	   established	  whether	  aging	   causes	   senescence,	   or	   whether	   senescence	   causes	   aging,	   though	   there	   is	  strong	  evidence	  to	  suggest	  that	  the	  two	  are	  often	  linked	  (Rodier	  and	  Campisi,	  2011;	  Wright	  and	  Shay,	  2002).	  Senescence	  can	  be	  triggered	  by	  both	  intrinsic	  and	  extrinsic	  factors	  (Itahana	  et	  al.,	  2004).	  Several	  cellular	  pathways	  have	  been	  implicated	  in	  the	  process	   of	   initiation	   of	   cellular	   senescence	   via	   intrinsic	   factors,	   including	   the	  p53/p21	   and	   p16/pRb	   pathways	   (Itahana	   et	   al.,	   2004).	   The	   length	   of	   cellular	  telomeres	   has	   also	   been	   implicated	   in	   cellular	   aging.	   Telomeres	   are	   non-­‐coding	  sequences	   at	   the	   end	   of	   eukaryotic	   chromosomes	   that	   protect	   the	   ends	   from	  recombination	  or	  non-­‐homologous	  end	  joining,	  and	  they	  guide	  accurate	  replication	  of	  DNA	  at	  the	  end	  of	  chromosomes	  (Counter	  et	  al.,	  1992).	  Telomeres	  are	  shortened	  progressively	   with	   each	   cell	   division	   in	   somatic	   cells	   (telomere	   attrition)	   unless	  telomerase	   is	   present.	   Telomerase	   is	   a	   ribonucleoprotein	   complex	   that	   extends	  telomeres	   and	   is	   found	   in	  most	   human	   cancer	   cells,	   but	   is	   only	   expressed	   at	   low	  levels	   in	   healthy,	   terminally	   differentiated	   cells.	   If	   telomeres	  decrease	   to	   a	   critical	  size,	   a	   cell	   will	   cease	   to	   divide	   and	   will	   enter	   senescence.	   Herbert	   et	   al.	   (1999)	  demonstrated	   that	   inhibition	   of	   telomerase	   in	   cells	   containing	   active	   telomerase	  leads	   to	   telomere	   shortening	   and	   reduction	   of	   the	   cellular	   lifespan.	   The	   external	  environment	   can	   also	   contribute	   to	   the	   entrance	   of	   a	   cell	   into	   senescence.	   High	  oxygen	  concentration	  has	  been	  shown	  to	  trigger	  the	  p16	  pathway	  in	  humans,	  which	  causes	  cell	  cycle	  arrest	  (Vijg	  and	  Campisi,	  2008).	  	  Researchers	  have	  been	  able	  to	  create	  immortalized	  cell	  line	  models	  in	  murine	  cells	  due	  to	  the	  cells’	  long	  telomeres.	  A	  cell	  line	  originating	  from	  a	  multicellular	  organism	  that	   has	   escaped	   cellular	   senescence	  by	  mutation	  or	   transformation	   is	   considered	  immortalized.	   Work	   has	   been	   done	   to	   immortalize	   human	   cells	   by	   transforming	  them	  with	   telomerase	   constructs	   (Counter	   et	   al.,	   1992).	   This	   procedure	   has	   been	  relatively	  successful	  in	  maintaining	  a	  cell’s	  proliferation	  status,	  but	  it	  cannot	  rescue	  cells	   in	   which	   the	   p16	   pathway	   has	   triggered	   cellular	   senescence	   (Coutu	   and	  Galipeau,	   2011).	   Immortalized	   cell	   lines	   are	   immensely	   useful	   in	   cellular	   biology	  research	   because	   they	   allow	   researchers	   to	   continually	   study	   the	   same	   cell	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population	  and	  can	  extend	  the	  lifespan	  of	  experiments.	  Unfortunately,	  immortalized	  cell	  lines	  are	  often	  susceptible	  to	  becoming	  cancerous	  (Vijg	  and	  Campisi,	  2008)	  and	  we	   would	   like	   to	   develop	   long-­‐lived	   or	   immortalized	   human	   cells	   that	   are	   not	  predisposed	  towards	  cancer	  for	  research	  and	  possible	  therapeutic	  applications.	  	  
5.4 p53	  as	  a	  Player	  in	  the	  Cell	  Cycle	  	  Eukaryotic	   cells	   must	   regulate	   their	   propagation	   and	   division	   in	   order	   to	   avoid	  accumulating	   deleterious	   mutations	   and	   undergoing	   cancerous	   transformation.	  Tumor	  suppressor	  protein	  p53	  is	  one	  of	  the	  most	  rigorously	  studied	  proteins	  in	  this	  regulation	   network.	   p53	   is	   activated	   by	   numerous	   cellular	   signals	   or	   conditions,	  including	   DNA	   damage,	   oxidative	   stress,	   osmotic	   shock,	   ribonucleotide	   depletion,	  and	   deregulation	   of	   oncogene	   expression.	   When	   p53	   is	   activated,	   its	   N-­‐terminal	  domain	   is	   phosphorylated	   at	   many	   residues	   and	   its	   half-­‐life	   is	   increased	  dramatically.	  This	  allows	  for	  more	  p53	  to	  accumulate	  in	  the	  cell.	  When	  the	  protein	  is	  phosphorylated,	  it	  also	  undergoes	  a	  conformational	  change	  that	  causes	  it	  to	  become	  an	  active	  transcriptional	  regulator.	  The	  phosphorylation	  of	  the	  N-­‐terminal	  domain	  is	  crucial	   because	   this	   region	   is	   the	   primary	   target	   of	   the	   protein	   kinases	   that	  transduce	  stress	  signals.	  	  The	  targeting	  kinases	  can	  be	  grouped	  into	  two	  families,	  the	  MAP	   kinases	   that	   are	   responsible	   for	   cellular	   stress	   signals,	   and	   the	   remaining	  kinases	  that	  are	  responsible	  for	  genome	  integrity	  checkpoint	  signaling.	  	  Additionally,	  p53	  plays	  a	  significant	  role	   in	  mediating	  apoptosis	   (programmed	  cell	  death)	  and	  contributing	  to	  the	  establishment	  of	  cellular	  senescence	  (Shaulian	  et	  al.,	  1997).	  Over-­‐expression	  of	  TP53	  is	  known	  to	  trigger	  apoptosis	  in	  cells	  and	  may	  do	  so	  if	   specific	   cellular	   factors	   are	   absent	   or	   if	   the	   cell	   senses	   excess	   activity	   of	  deleterious	   proteins.	   p53	   is	   translated	   at	   higher	   rates	   upon	   genotoxic	   stress,	   and	  p53’s	  target	  genes	  are	  selectively	  activated.	  These	  include	  MDM2,	  BAX,	  WAF1/CIP1,	  and	  GADD45.	   Interestingly,	   several	   splice	   variants	   of	   the	  MDM2	   protein	   can	   bind	  p53	  (Olson,	  1993)	  and	  tag	  it	  for	  ubiquitin-­‐mediated	  degradation.	  In	  this	  way,	  MDM2	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activity	   can	   modulate	   p53	   activity	   and	   form	   a	   negative	   feedback	   loop,	   though	  complexes	   of	  MDM2	  and	  p53	   are	   not	   always	   detectable	   in	   cells	   co-­‐expressing	   the	  two	  genes.	  The	  negative	  regulation	  of	  p53	  allows	  cells	   to	  keep	  p53	   levels	   in	  check	  (Shaulian	  et	  al.,	  1997).	  Overexpression	  of	  MDM2	  has	  been	  used	  to	  immortalize	  cell	  lines	  (Finlay,	  1993)	  and	  can	  rescue	  cells	  from	  p53-­‐triggered	  senescence	  (Chen	  et	  al.,	  1996;	  Haupt	  et	  al.,	  1996).	  	  The	  human	  TP53	  gene	  encodes	  a	  full-­‐length	  protein	  of	  393	  amino	  acids	  (GenBank:	  BAC16799.1,	  NCBI,	  NIH),	  and	  it	  is	  relatively	  well	  conserved	  between	  mammalian	  species	  (Walker	  et	  al.	  1999).	  The	  gene	  has	  been	  mapped	  to	  human	  chromosome	  17.	  Binding	  of	  p53	  to	  DNA	  can	  stimulate	  CDKN1A,	  the	  gene	  encoding	  p21,	  which	  has	  also	  been	  linked	  to	  intrinsic	  triggering	  of	  cellular	  senescence	  (Coutu	  and	  Galipeau,	  2011).	  p21	  and	  a	  cell	  division	  kinase	  (Cdk2)	  interact	  to	  inhibit	  the	  cell’s	  progression	  to	  the	  next	  stage	  of	  the	  cell	  cycle.	  In	  the	  absence	  of	  functional	  p53,	  transcription	  of	  p21	  is	  not	  activated,	  and	  cells	  can	  escape	  the	  cell	  cycle	  checkpoints	  for	  appropriate	  cell	  division.	  	  For	  a	  summary	  of	  p53’s	  interaction	  network	  and	  the	  cellular	  stresses	  that	  activate	  it,	  see	  Figure	  5.3. 
	  
Figure	  5.3	  p53	  interaction	  network	  and	  pathways	  to	  senescence.	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5.5 Extending	  Lifespan	  in	  Differentiated	  Human	  Cells	  	  Research	   has	   shown	   that	   human	   somatic	   cells	   can	   respond	   to	   manipulation	   of	  oxygen	   concentration	   and	   supplementation	   with	   FGF2	   via	   up-­‐regulation	   of	   some	  genes	   associated	   with	   pluripotency.	   These	   genes	   include	   LIN28,	   Rex1,	   POU5F1	  (OCT4	  protein),	  SOX2,	  and	  NANOG	  (Page	  et	  al.,	  2009).	  	  Previous	   studies	   by	   Takahashi,	   et	   al.	   (2007a	   and	   b)	   showed	   that	   transfection	   of	  human	   fibroblasts	   with	   genes	   for	   stem	   cell-­‐associated	   transcription	   factors	   is	  sufficient	   to	   induce	   reversion	   to	   a	  pluripotent	   state.	  The	   transfection	  of	   cells	  with	  transcripts	   for	  POU5F1,	  SOX2,	  NANOG,	   and	  LIN28	   and	  subsequent	  activation	  of	   the	  genes	  seems	  to	  be	  enough	  to	  begin	  the	  process	  of	  returning	  cells	  to	  pluripotency	  and	  for	  the	  expression	  of	  embryonic	  stem	  cell	  characteristics	  (Yu	  et	  al,	  2007;	  Page	  et	  al.,	  2009).	  	  	  Our	  lab	  has	  shown	  that	  fibroblasts	  grown	  in	  a	  humidified	  environment	  at	  37˚C	  and	  5%	  O2,	  5%	  CO2,	  and	  90%	  N2	  and	   in	  media	  supplemented	  with	  FGF-­‐2	  were	  able	   to	  undergo	   70	   population	   doublings	   over	   their	   proliferative	   lifespan.	   A	   control	  population	   of	   fibroblasts	   grown	   in	   atmospheric	   oxygen	   concentration	   (19%)	   and	  without	  FGF-­‐2	  only	  underwent	  33	  population	  doublings	  by	  comparison	  (Page	  et	  al.,	  2009).	   The	   conditions	   described	   for	   the	   experimental	   group	   (5%	   O2	   and	   FGF-­‐2)	  have	   been	   termed	   induced	   regeneration	   competent	   (iRC)	   conditions	   and	   will	   be	  referred	   to	   as	   such	   throughout	   this	   project	   (Kashpur	   et	   al.,	   2013).	   The	   cells	   are	  referred	   to	   as	   “regeneration	   competent”	   because	   they	   express	   stem-­‐cell	   marker	  genes	  and	  are	  therefore	  demonstrate	  phenotypes	  associated	  with	  cellular	  plasticity.	  Therefore,	   they	  are	   responsive	   to	   signals	   that	   stimulate	   reentry	   into	   the	   cell	   cycle	  (Stocum,	   2002)	   and	   may	   participate	   in	   regenerative	   tissue	   healing	   (Page	   et	   al.,	  2011).	  	  The	   ability	   to	   return	   differentiated	   somatic	   cells	   to	   a	   more	   plastic	   state	   has	  significant	   implications	   for	   development	   of	   patient-­‐specific	   cells	   for	   therapy	   and	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new	  models	   for	  disease	  progression	  research	  (Page	  et	  al.,	  2009).	  Our	   lab	  has	  been	  able	  to	  produce	   iRC	  cells	   from	  terminally	  differentiated	  human	  dermal	   fibroblasts;	  bringing	  us	  a	  step	  closer	  to	  useful	  applications	  of	  developmentally	  plastic	  cells.	  The	  aim	   of	   the	   project	   was	   to	   investigate	   factors	   that	   may	   play	   a	   role	   in	   extended	  lifespan	   of	   iRC	   cells.	   A	   better	   understanding	   of	   these	   factors	  will	   help	   us	   identify	  molecular	   mechanisms	   regulating	   the	   switch	   between	   extended	   life	   span	   and	  immortalization	  during	  oncogenic	   transformation,	   bringing	  us	   closer	   to	  producing	  therapeutically	  relevant,	  non-­‐tumorigenic	  autologous	  cell	  sources	  and	  replacing	  the	  need	  for	  embryonic	  stem	  cells	  for	  cell	  therapy.	  	  I	   investigated	   the	   relative	   protein	   abundance	   of	   tumor	   suppressor	   protein	   p53	  throughout	   the	   lifespan	   of	   iRC	   cells	   to	   determine	  whether	   the	   cells’	   extended	   life	  span	  was	  paralleled	  by	  a	  decrease	  in	  p53-­‐mediated	  cellular	  senescence	  signaling.	  To	  achieve	   this	  goal,	  human	   fibroblasts	  were	  grown	  under	   iRC	  conditions	   (as	  defined	  above	   and	   described	   in	   Page,	   et	   al.,	   2009)	   and	   partial	   iRC	   conditions	   (either	   low	  oxygen	   concentration	   or	   supplementation	   with	   FGF2)	   and	   total	   protein	   and	   RNA	  collected	   during	   the	   first	   30	   days	   of	   exposure	   to	   a	   particular	   set	   of	   culture	  conditions.	  I	  was	  unable	  to	  collect	  samples	  during	  the	  later	  portions	  of	  the	  cells’	  in	  
vitro	   lifespans	  due	  to	  the	  time	   limitations	  of	   the	  project.	  These	  samples	  were	  used	  for	  determination	  of	  p53	  transcript	  by	  RT-­‐PCR	  and	  qRT-­‐PCR,	  and	  for	  determination	  of	  p53	  protein	   levels	  by	  Western	  blotting	  p53.	  Results	  were	  compared	   to	   samples	  gathered	  from	  fibroblasts	  grown	  under	  control	  culture	  conditions	  (19%	  O2	  and	  with	  media	   not	   supplemented	   with	   FGF2).	   We	   hypothesized	   that	   p53	   protein	   levels	  would	  rise	  with	  increasing	  population	  doublings	  in	  iRC	  cells	  in	  a	  similar	  pattern	  to	  the	  accumulation	  of	  p53	  in	  control	  cells,	  though	  it	  would	  take	  longer	  to	  accumulate	  to	   comparable	   levels.	   In	   addition	   to	   p53,	   I	   investigated	   levels	   of	   p53-­‐regulator	  MDM2	  and	  levels	  of	  two	  G1/S	  phase	  cell	  cycle	  inhibitors,	  p21	  and	  p16.	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6 Materials	  and	  Methods	  
6.1 Cell	  Culture	  	  Human	   dermal	   fibroblasts	   CRL-­‐2352	   cells	   were	   purchased	   from	   American	   Tissue	  Culture	   Collection	   (ATCC;	   Manassas,	   VA).	   This	   dermal	   fibroblast	   cell	   line	   was	  derived	  from	  a	  skin	  biopsy	  from	  a	  below-­‐the-­‐knee	  amputation	  conducted	  on	  a	  24-­‐year-­‐old,	  Caucasian	  male	  suffering	  from	  lymphoma,	  though	  the	  tissue	  of	  origin	  was	  unaffected.	   The	   ATCC	   cell	   line	   description	   states	   that	   CRL-­‐2352	   cells	   typically	  senesce	   after	   about	   32	   population	   doublings,	   and	   the	   purchased	   cells	   had	  undergone	  three	  population	  doublings	  beyond	  their	  primary	  derivation.	  	  Cells	   were	   grown	   in	   human	   dermal	   fibroblast	   (hDF)	   medium	   consisting	   of	  DMEM:Ham’s	  F12	  (50:50,	  MediaTech)	  with	  10%	  Fetalclone	  III	  (Hyclone,	  Logan,	  UT).	  Prior	  to	  use,	  the	  DMEM	  (without	  L-­‐Gln	  or	  phenol	  red)	  was	  supplemented	  with	  4	  mM	  fresh	   L-­‐Gln	   (MediaTech,	  Manassas,	   VA).	   The	   four	   experimental	   culture	   conditions	  were	  as	  follows:	  1. hDF	  medium	  placed	  in	  ambient	  oxygen	  (19%)	  2. hDF	   medium	   supplemented	   with	   4	   ng/mL	   recombinant	   human	   fibroblast	  growth	  factor	  (FGF-­‐2)	  (Chemicon,	  Temecula,	  CA,	  or	  Protide,	  Lake	  Zurich,	  IL)	  placed	  in	  ambient	  oxygen	  (19%).	  3. 	  hDF	  medium	  placed	  in	  5%	  oxygen	  4. hDF	   medium	   supplemented	   with	   4	   ng/mL	   recombinant	   human	   fibroblast	  growth	  factor	  (FGF-­‐2)	  (Chemicon,	  Temecula,	  CA,	  or	  Protide,	  Lake	  Zurich,	  IL)	  placed	  in	  5%	  oxygen.	  	  Cells	  were	  seeded	  at	  100,000	  cells	  per	  60-­‐mm	  dish	  (Nunclon)	  at	  each	  passage	  and	  media	  was	  replaced	  every	  fourth	  day	  if	  the	  cells	  were	  not	  yet	  confluent.	  When	  cells	  were	  passaged,	  the	  media	  was	  aspirated	  from	  the	  plate,	  the	  cells	  were	  rinsed	  with	  PBS	   (Corning	   Cellgro,	   Manassas,	   VA),	   and	   then	   the	   cells	   were	   then	   incubated	   in	  trypsin	  (Corning	  Cellgro,	  Manassas,	  VA)	  at	  37˚C	  for	  5	  minutes.	  The	  cells	  and	  trypsin	  were	   then	  mixed	  with	   fresh	  media,	   and	   the	   cell	   concentration	  was	  determined	  by	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counting	  an	  aliquot	  of	  the	  mixture	  with	  a	  haemocytometer.	  At	  each	  possible	  passage,	  the	   cells	   remaining	   after	   plating	   were	   centrifuged	   at	   10xg	   for	   5	   minutes,	   media	  aspirated,	  and	  the	  pellet	  resuspended	  in	  PBS.	  The	  centrifugation	  was	  repeated	  and	  the	   PBS	   wash	   was	   aspirated.	   The	   resulting	   cell	   pellet	   was	   then	   snap	   frozen	   by	  dipping	  the	  centrifuge	  tube	  containing	  it	  in	  liquid	  nitrogen.	  Once	  pellets	  were	  frozen,	  they	  were	  stored	  at	  -­‐80˚C	  until	  the	  pellets	  were	  used	  for	  RNA	  or	  protein	  isolation.	  
 
6.2 RNA	  Isolation	  	  Total	  RNA	  was	   isolated	   from	  cell	  pellets	  using	  Trizol	   following	   the	  manufacturer’s	  protocol	   (Life	   Technologies).	   Trizol	  was	   added	   to	   sample	   pellets	   and	   the	  mixture	  was	   passed	   repeatedly	   through	   a	   25-­‐gauge	   syringe	   to	   break	   up	   the	   pellet.	   The	  addition	  of	  chloroform,	  agitation,	  and	  then	  centrifugation	  separated	  the	  mixture	  into	  the	  expected	  three	  phases:	  phenol-­‐chloroform,	  interphase,	  and	  aqueous	  phases.	  The	  aqueous	   phase	   was	   isolated	   and	   used	   for	   RNA	   precipitation.	   Precipitation	   was	  induced	   by	   addition	   of	   isopropanol	   and	   isolated	   by	   centrifugation.	   The	   resulting	  pellet	   from	   the	   most	   recent	   centrifugation	   was	   saved	   and	   washed	   with	   ethanol,	  vortexed,	  and	  dried	  briefly.	  The	  RNA	  was	  resuspended	  in	  25	  µL	  of	  deionized	  water	  and	  its	  concentration	  was	  determined	  using	  the	  NanoDrop	  spectrophotometer.	  	  
6.3 Reverse	  Transcriptase	  Polymerase	  Chain	  Reaction	  (RT-­‐PCR)	  	  Complementary	   DNA	   (cDNA)	   was	   synthesized	   using	   Quanta	   BioSciences’	   qScript	  cDNA	  SuperMix	  according	  to	  the	  manufacturer’s	  protocol.	  Reagents	  and	  1	  µg	  of	  RNA	  were	   combined	   for	   each	  20-­‐µL	   reaction	   in	  0.2	  mL	  micro-­‐tubes	  and	   incubated	   in	   a	  thermocycler	   according	   to	   the	  manufacturer’s	   specifications	   (Quanta	  BioSciences).	  cDNA	  was	  amplified	  using	  PCR	  with	  GoTaq	  DNA	  Polymerase	  (Promega).	  All	  RT-­‐PCR	  reactions	  had	  a	  final	  concentration	  of	  200	  nM	  of	  each	  primer.	  Sequences	  of	  primers	  used	  are	  described	  in	  Table	  6.1.	  The	  samples	  were	  held	  at	  95˚C	  for	  5	  minutes,	  at	  a	  primer-­‐specific	  annealing	  temperature	  (54˚C	  -­‐60˚C)	  15	  seconds,	  72˚C	  for	  30	  seconds	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and	  the	  cycle	  repeated	  29	  times.	  After	  terminal	  extension	  at	  72˚C	  for	  7	  minutes,	  the	  samples	  were	  held	  at	  4˚C	  until	  analyzed.	  Samples	  were	  run	  on	  a	  1.5%	  agarose	  gel	  in	  TAE	   buffer	   with	   ethidium	   bromide	   at	   100	   V.	   The	   gel	   was	   imaged	   with	   a	   BioRad	  Image	  Station.	  	  
Table	  6.1	  RT-­‐PCR	  primer	  design	  and	  cycling	  conditions.	  





p53	   5’-­‐CTC	  AGA	  TAG	  CGA	  TGG	  TCT	  GGC-­‐3’	   5’-­‐GCC	  CAC	  GGA	  TCT	  GAA	  GGG-­‐3’	   54˚C	  
p21	  	   5’-­‐CCG	  AAG	  TCA	  GTT	  CCT	  TGT	  GGA	  G-­‐3’	   5’-­‐CAA	  GGG	  TAC	  AAG	  ACA	  GTG	  ACA	  GG-­‐3’	   54˚C	  
Actin	  (Loading	  
Control)	  
5’-­‐TCT	  GGC	  ACC	  ACA	  CCT	  TCT	  ACA	  A-­‐3’	   5’-­‐CTT	  CTC	  CTT	  AAT	  GTC	  ACG	  CAC	  G-­‐3’	   58˚C	  	  
6.4 Quantitative	  Reverse	  Transcriptase	  Polymerase	  Chain	  Reaction	  (qRT-­‐PCR)	  	  
The	  cDNA	  was	  also	  used	  for	  amplification	  with	  for	  quantitative	  qRT-­‐PCR	  and	  with	  Power	  SYBR	  Master	  
Mix	  (Life	  Technologies).	  PCR	  conditions	  were	  suggested	  by	  the	  manufacturer’s	  protocol.	  Primer	  
sequences	  are	  shown	  in	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Table	   6.2.	   Cycling	   conditions	   were	   as	   follows:	   95˚C	   for	   10	   minutes,	   95˚C	   for	   15	  seconds,	  60˚C	  for	  1	  minute,	  Repeat	  steps	  2-­‐3	  40	  times,	  Melt	  curve,	  Hold	  at	  4˚C.	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Table	  6.2	  qRT-­‐PCR	  primer	  design	  and	  specifications.	  





p53	   5’-­‐GTG	  TTT	  GTG	  CCT	  GTC	  CTG	  GGA	  G-­‐3’	   5’-­‐GCT	  CTC	  GGA	  ACA	  TCT	  CGA	  AGC	  C-­‐3’	   60˚C	  
p21	  	   5’-­‐CAC	  TGT	  CTT	  GTA	  CCC	  TTG	  TGC	  C-­‐3’	   5’-­‐TTC	  CTC	  TTG	  GAG	  AAG	  ATC	  AGC	  CG-­‐3’	   60˚C	  
p16	  	   5’-­‐GAG	  CAC	  TCA	  CGC	  CCT	  AAG-­‐3’	   5’-­‐AGT	  GTG	  ACT	  CAA	  GAG	  AAG	  CCA	  G-­‐3’	   60˚C	  
MDM2	  	   5’-­‐CCT	  TCT	  GAT	  CCT	  TAG	  TTT	  CTC	  TCT	  CC-­‐3’	   5’-­‐TCA	  TTT	  ACA	  TAG	  CAC	  CAA	  ATA	  TAA	  GAG	  CC-­‐3’	   60	  ˚C	  
Actin	  (Loading	  
Control)	  
5’-­‐AGA	  GCT	  ACG	  AGC	  TGC	  CTG	  AC-­‐3’	  	   5’-­‐	  GGA	  TGC	  CAC	  AGG	  ACT	  CCA-­‐3’	   60˚C	  	  For	  qRT-­‐PCR	  analysis,	  the	  Ct	  values	  for	  the	  gene	  of	  interest	  were	  normalized	  relative	  to	   the	   Ct	   values	   for	   actin	   in	   order	   to	   account	   for	   differences	   in	   amount	   of	   cDNA	  template	   loaded	   (delta	   Ct).	   The	   delta	   Ct	   values	   were	   compared	   relative	   to	   the	  untreated	  control	  (ambient	  oxygen:	  19%,	  no	  FGF2)	  in	  order	  to	  calculate	  the	  change	  in	  transcript	  expression	  levels	  conferred	  by	  each	  treatment.	  	  
6.5 Protein	  Isolation	  and	  Western	  Blotting	  
	  Total	  protein	  was	  isolated	  from	  fibroblast	  cell	  pellets	  with	  DK	  cell	   lysis	  buffer	   	  (5X	  stock:	   200	   mM	   Tris	   pH	   7.5,	   750	   mM	   NaCl,	   40%	   glycerol,	   0.0626%	   Triton	   X-­‐100,	  0.025%	   Tween	   20,	   0.1%	   NP-­‐40)	   supplemented	   with	   complete	   protease	   inhibitor	  cocktail	  (PIC,	  Santa	  Cruz	  Biotechnology)	  and	  sonication	  of	  the	  sample	  on	  ice.	  Protein	  concentration	   was	   determined	   with	   the	   Bradford	   assay	   kit,	   according	   to	   the	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manufacturer’s	   protocol	   (Thermo	   Scientific).	   Protein	   concentrations	   were	  determined	   using	   the	   “Standard	   Microplate	   Protocol”	   in	   a	   96-­‐well	   format.	  Absorbance	  readings	  for	  each	  of	  the	  samples	  were	  imported	  to	  Microsoft	  Excel	  and	  normalized	  by	  subtracting	  the	  absorbance	  of	  the	  blank	  standard.	  	  	   𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  𝑠𝑎𝑚𝑝𝑙𝑒  𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = (𝑠𝑎𝑚𝑝𝑙𝑒  𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒)− (𝑏𝑙𝑎𝑛𝑘  𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒)	  	  The	   normalized	   sample	   absorbances	   of	   the	   standards	   were	   graphed	   versus	   the	  protein	   concentrations.	   Protein	   samples	   with	   unknown	   concentrations	   were	  assigned	   arbitrary	   values	   to	   visualize	   which	   dilution	   of	   the	   sample	   was	   most	  appropriate	   for	   the	   linear	   range	  of	   the	  standard	  curve.	  This	  can	  be	  seen	   in	  Error!	  
Reference	   source	   not	   found.	   and	   Error!	   Reference	   source	   not	   found..	   Two	  figures	   and	   two	   standard	   curves	   were	   generated	   because	   there	   were	   too	   many	  samples	  for	  a	  single	  96-­‐well	  plate.	  	  	  Equal	   amounts	   of	   protein	   lysate	   and	   denaturing	   2X	   sample	   buffer	   (BioRad	  Laboratories)	   were	   mixed	   and	   heated	   to	   100˚C	   for	   5	   minutes	   prior	   to	   using	   the	  sample	  for	  gel	  electrophoresis.	  	  Proteins	   were	   separated	   on	   12%	   SDS-­‐PAGE	   gels	   and	   transferred	   to	   PVDF	  membranes	  (BioRad	  Laboratories)	  using	  Towbin’s	  transfer	  buffer	  (25	  mM	  Tris,	  192	  mM	  glycine,	  20%	  methanol,	  and	  0.037%	  SDS).	  The	  membranes	  were	  blocked	  with	  Tween-­‐Tris-­‐buffered	   saline	   (TBS-­‐T:	   25	  mM	  Tris,	   137	  mM	  NaCl,	   2,7	  mM	  KCl,	   0.2%	  Tween),	  and	  5%	  dry	  milk.	  1%	  milk	   in	  TBS-­‐T	  was	  used	   for	  primary	  and	  secondary	  antibody	   incubations.	   	   Primary	   mouse	   antibodies	   against	   p53	   (Santa	   Cruz	  Biotechnologies)	   and	   rabbit	   antibodies	   against	   actin	   (Sigma)	  were	   used.	   Between	  antibody	   incubations,	   membranes	   were	   washed	   three	   times	   with	   TBS-­‐T.	   Primary	  antibodies	   were	   detected	   with	   HRP-­‐conjugated	   goat	   anti-­‐mouse	   and	   anti-­‐rabbit	  secondary	   antibodies,	   respectively,	   and	   signal	   detected	   by	   chemiluminescence	  (Luminol;	  Santa	  Cruz	  Biotechnologies).	  	  Images	  were	  obtained	  with	  a	  BioRad	  Image	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Station	  and	  the	  intensities	  of	  bands	  were	  quantified	  using	  densitometry	  analysis	  in	  ImageJ	  software.	  	  
6.6 Flow	  Cytometry	  	  Cells	  were	  pelleted	  as	  before	   to	  wash	  out	  media	  and	  resuspended	   in	  70%	  ethanol	  for	  fixation	  prior	  to	  performing	  flow	  cytometry	  on	  the	  samples.	  Samples	  were	  then	  treated	  with	  RNase	  A	  and	  stained	  with	  propidium	  iodide	  according	  to	  the	  protocol	  written	  by	  Piotr	  Pozarowski	  and	  Zbigniew	  Darzynkiewicz,	  “Analysis	  of	  Cell	  Cycle	  by	  Flow	  Cytometry”.	  	  	  The	  flow	  cytometry	  events	  corresponding	  to	  fragments	  of	  DNA,	  particulate	  matter,	  and	   cellular	   debris	   were	   excluded	   from	   analysis	   based	   on	   their	   low	   fluorescence	  (565-­‐605	   nm	   range,	   FL-­‐2	   channel).	   The	   remaining	   events	   were	   assumed	   to	   be	  derived	   from	   cells	   living	   at	   the	   time	   of	   fixation.	   Signals	   recorded	   from	   the	   FL-­‐2	  channel	  were	  plotted	  as	  event	  count	  as	  a	  function	  of	  FL-­‐2	  intensity.	  	  
7 Results	  	  
7.1 Population	  Doublings	  of	  Fibroblasts	  Cultured	  Under	  Different	  Conditions	  
	  Human	   dermal	   fibroblasts	   (CRL-­‐2352)	   were	   grown	   under	   the	   following	  experimental	   conditions:	   hDF	   media	   without	   FGF2	   and	   in	   19%	   O2,	   hDF	   media	  without	  FGF2	  and	  in	  5%	  O2,	  hDF	  media	  with	  FGF2	  and	  in	  19%	  O2,	  and	  hDF	  media	  with	   FGF2	   and	   in	   5%	  O2.	   The	   concentration	   of	   cells	  was	   determined	   by	   counting	  cells	  using	  a	  0.1-­‐mm	  Haemocytometer	  at	   each	  passage.	  Cell	   counts	  were	   recorded	  and	  Microsoft	  Excel	  was	  used	  to	  calculate	  the	  cumulative	  population	  doublings	  each	  cell	   population	   had	   undergone	   at	   each	   passage	   (Figure	   7.1).	   The	   calculations	   for	  population	  doublings	  were	  performed	  using	  the	  following	  formulas:	  	  
Concentration	  of	  cells	  on	  plate	  to	  be	  passaged:	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𝐶𝑒𝑙𝑙𝑠𝑚𝐿 = #  𝑜𝑓  𝑐𝑒𝑙𝑙𝑠  𝑐𝑜𝑢𝑛𝑡𝑒𝑑 /4 ∗ 10,000	  
Total	  Number	  of	  cells	  on	  plate	  to	  be	  passaged:	  𝑇𝑜𝑡𝑎𝑙  #  𝑜𝑓  𝐶𝑒𝑙𝑙𝑠 = 𝑐𝑒𝑙𝑙𝑠𝑚𝐿 ∗ (𝑣𝑜𝑙𝑢𝑚𝑒  𝑜𝑓  𝑚𝑒𝑑𝑖𝑎  𝑜𝑛  𝑝𝑙𝑎𝑡𝑒  𝑡𝑜  𝑏𝑒  𝑝𝑎𝑠𝑠𝑎𝑔𝑒𝑑)	  
Number	  of	  population	  doublings	  since	  the	  previous	  passage:	  
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛  𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠   = 𝑙𝑛 𝑇𝑜𝑡𝑎𝑙  #  𝑜𝑓𝐶𝑒𝑙𝑙𝑠#  𝑜𝑓  𝐶𝑒𝑙𝑙𝑠  𝑃𝑙𝑎𝑡𝑒𝑑  𝑎𝑡  𝑃𝑟𝑒𝑣𝑖𝑜𝑢𝑠  𝑃𝑎𝑠𝑠𝑎𝑔𝑒𝑙𝑛 2 	  
Population	  doubling	  rate	  since	  the	  previous	  passage:	  𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛  𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔  𝑅𝑎𝑡𝑒 = 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛  𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠𝐷𝑎𝑦𝑠  𝑆𝑖𝑛𝑐𝑒  𝑃𝑟𝑒𝑣𝑖𝑜𝑢𝑠  𝑃𝑎𝑠𝑠𝑎𝑔𝑒	  
Cumulative	  population	  doublings:	  𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒  𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛  𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠= Σ 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛  𝐷𝑜𝑢𝑏𝑙𝑖𝑛𝑔𝑠  𝑓𝑟𝑜𝑚  𝑎𝑙𝑙  𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠  𝑝𝑎𝑠𝑠𝑎𝑔𝑒𝑠 	  	  Treatment	  with	  FGF2	  and	   low	  oxygen	  started	  after	  18	  days	   in	  culture	  (designated	  Day	  0).	  Samples	  for	  RT-­‐PCR,	  qRT-­‐PCR,	  and	  Western	  blotting	  were	  collected	  on	  Days	  7,	  18,	  21,	  22,	  27,	  32,	  and	  34	  after	   treatment	  began.	  The	  cell	  populations	  were	  still	  growing	  and	  continued	  to	  be	  passaged,	  though	  they	  had	  begun	  to	  exhibit	  phenotypic	  characteristics	  of	  senescent	  cells,	  including	  becoming	  increasingly	  vacuolated.	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Figure	   7.1	   Cumulative	   population	   doublings	   of	   fibroblasts	   grown	   under	   the	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later	  passages.	  The	  combination	  of	  supplementation	  of	  media	  with	  FGF2	  and	  growth	  in	  low	  oxygen	  concentrations	  increased	  the	  rate	  that	  a	  cell	  progressed	  through	  the	  cell	  cycle.	  Supplementation	  of	  media	  with	  FGF2	  was	  sufficient	  to	  increase	  the	  rate	  at	  which	  the	  cells	  divided,	  while	  culturing	  at	  a	  lower	  oxygen	  concentration	  reduced	  the	  population-­‐doubling	  rate	  (Figure	  7.1).	  	  	  
7.2 mRNA	  Expression	  of	  p53	  and	  p21	  in	  Human	  Dermal	  Fibroblasts	  Grown	  
Under	  Different	  Conditions	  	  Total	   RNA	   was	   isolated	   from	   cell	   pellets	   harvested	   during	   the	   treatment	   time	  course,	   cDNA	  was	   synthesized,	   and	  RT-­‐PCR	  was	   run	   for	  p53,	   p21,	   and	   actin	   (load	  control)	  (Figure	  7.2).	  	  
	  
Figure	   7.2	   RT-­‐PCR	   for	   p53,	   p21,	   and	   actin.	   No	   template	   control	   (NTC)	   and	  
reverse	  transcriptase	  negative	  (RT-­‐)	  controls	  are	  shown.	  	  Transcript	   levels	  of	  p53	  appear	   to	  accumulate	  over	   time	  and	   then	  be	  degraded	  or	  down	  regulated	   in	  older	  cells	   treated	  with	  FGF2,	  while	  untreated	  cells	  continue	   to	  accumulate	  p53	  mRNA	  transcripts.	  Relative	  p21	  transcript	   levels	  appear	  relatively	  constant	  throughout	  the	  time	  course	  studied.	  	  	  The	   same	   cDNA	   samples	   were	   also	   used	   in	   performing	   qRT-­‐PCR	   for	   p53,	   p21,	  MDM2,	  and	  p16	  (Figure	  7.3,	  Figure	  7.4,	  Figure	  7.5,	  and	  Figure	  7.6).	  The	  expression	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fold	  change	  of	  each	  gene	  of	  interest	  was	  normalized	  to	  the	  first	  sample	  (Day	  7)	  and	  to	  actin.	  	  
	  
	  
Figure	  7.3	  Analysis	  of	  the	  qRT-­‐PCR	  for	  p53	  represented	  as	  the	  fold	  change	  in	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  5%	  O2,	  FGF2	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Figure	  7.4	  Analysis	  of	  the	  qRT-­‐PCR	  for	  p21	  represented	  as	  the	  fold	  change	  in	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  FGF2	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Figure	  7.5	  Analysis	  of	  the	  qRT-­‐PCR	  for	  MDM2	  represented	  as	  the	  fold	  change	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Figure	  7.6	  Analysis	  of	  the	  qRT-­‐PCR	  for	  p16	  represented	  as	  the	  fold	  change	  in	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7.3 Levels	  of	  p53	  Protein	  in	  Human	  Dermal	  Fibroblasts	  Grown	  Under	  Different	  
Conditions	  	  Total	  protein	  was	  isolated	  from	  cell	  pellets	  harvested	  at	  the	  same	  time	  points	  used	  for	   the	   RNA.	   The	   normalized	   sample	   absorbances	   of	   the	   standards	  were	   graphed	  versus	   the	   protein	   concentrations.	   Protein	   samples	  with	   unknown	   concentrations	  were	  assigned	  arbitrary	  values	  to	  visualize	  which	  dilution	  of	   the	  sample	  was	  most	  appropriate	  for	  the	  linear	  range	  of	  the	  standard	  curve.	  	  This	  can	  be	  seen	  in	  Figure	  7.7	  and	  Figure	  7.8.	  Two	  figures	  and	  two	  standard	  curves	  were	  generated	  because	  there	  were	  too	  many	  samples	  for	  a	  single	  96-­‐well	  plate.	  	  
	  
Figure	  7.7	  Bradford	  standard	  curve	  for	  the	  first	  of	  two	  plates	  run	  to	  determine	  
sample	  protein	  concentrations.	  Y=0.0005x+0.0232;	  R2=0.99218.	  















BSA	  Concentration	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BSA	  Standard	  Curve	  for	  Bradford	  Assay	  
BSA	  Standard	  Curve	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Figure	  7.8	  Bradford	  standard	  curve	  for	  the	  second	  of	  two	  plates	  run	  to	  
determine	  sample	  protein	  concentrations.	  Y=0.0005x+0.0215;	  R2=0.98722.	  	  Protein	   levels	  were	   standardized	  prior	   to	   loading	  on	  SDS-­‐PAGE	  gels,	   and	  Western	  blots	  were	  performed	  for	  p53	  and	  actin	  (load	  control)	  (Figure	  7.9	  and	  Figure	  7.10).	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Figure	  7.9	  A)	  Western	  blot	  for	  p53	  and	  actin	  control	  in	  cells	  treated	  with	  FGF2.	  
B)	   Densitometry	   quantification	   of	   p53	  Western	   blot	   results	   for	   samples	   not	  
treated	  with	  FGF2.	  Values	  are	  calculated	  relative	  to	  actin.	  	  Each	   sample	  was	   loaded	  with	   a	   relatively	   consistent	   amount	   of	   protein	   (see	   actin	  bands).	   p53	   appears	   to	   accumulate	   over	   time	   in	   samples	  without	   FGF2,	  while	   the	  samples	  with	  FGF2	  show	  the	  same	  drop	  in	  protein	  expression	  at	  the	  final	  time	  point	  that	  was	  noted	   in	   the	  qRT-­‐PCR	   (Figure	  7.3).	  The	   lower	  oxygen	   samples	   appear	   to	  have	  reduced	  levels	  of	  protein	  compared	  to	  the	  higher	  oxygen	  samples	  in	  both	  the	  presence	  and	  absence	  of	  FGF2.	  	  	  The	   results	   of	   the	  Western	  blots	   in	  Figure	  7.9A	   and	  Figure	  7.10A	  were	  quantified	  using	   densitometry	   analysis	   and	   ImageJ	   software	   (Figure	   7.9B	   and	   Figure	   7.10B).	  	  The	  reduction	  of	  culture	  oxygen	  concentration	  in	  cells	  treated	  with	  FGF2	  appears	  to	  lower	   p53	   protein	   concentration	   at	  most	   time	   points	   relative	   to	   cells	   cultured	   in	  ambient	  oxygen.	  Both	  treatment	  conditions	  treated	  with	  FGF2	  exhibit	  an	  increase	  in	  p53	   protein	   concentration	   until	   the	   final	   time	   point	   sampled,	   when	   p53	   protein	  levels	  drop	  (Figure	  7.9).	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Figure	  7.10	  A)	  Western	  blot	  for	  p53	  and	  actin	  control	  in	  cells	  not	  treated	  with	  
FGF2.	  B)	  Densitometry	  quantification	  of	  p53	  Western	  blot	  results	  for	  samples	  
not	  treated	  with	  FGF2.	  Values	  are	  calculated	  relative	  to	  actin.	  	  Lowering	  oxygen	  concentration	   in	   cells	  not	   treated	  with	  FGF2	   lowers	  p53	  protein	  levels.	  p53	  protein	  accumulates	  at	  early	  passages	  in	  control	  cells	  and	  then	  remains	  relatively	  constant	  throughout	  the	  time	  course	  studied	  (Figure	  7.10).	  	  	  The	  quantification	  of	  the	  Western	  blots	  (Figure	  7.9B	  and	  Figure	  7.10B)	  supports	  the	  observations	  stated	  about	  the	  blots	  (Figure	  7.9A	  and	  Figure	  7.10A).	  Treatment	  with	  FGF2	  appears	  to	  cause	  a	  reduction	  in	  p53	  protein	  levels	  at	  the	  final	  time	  point	  after	  gradual	   accumulation,	   while	   the	   lower	   oxygen	   concentration	   lowers	   the	   protein	  levels	  overall.	  	  	  
7.4 Flow	  Cytometry	  	  Cell	   cycle	   flow	   cytometry	   was	   performed	   on	   cell	   samples	   gathered	   and	   fixed	   in	  ethanol	  after	  21	  and	  22	  passages	  (No	  FGF2	  and	  FGF2	  samples,	  respectively).	  Signals	  recorded	   from	  the	  FL-­‐2	  channel	  were	  plotted	  as	  event	  count	  as	  a	   function	  of	  FL-­‐2	  intensity.	   All	   four	   samples	   show	   characteristic,	   bimodal	   distributions	   with	   an	  associated	  non-­‐zero	  baseline	  between	   the	  peaks.	  The	   lower	   intensity	  peak	   in	  each	  plot	  represents	  the	  phase	  during	  which	  a	  cell	  is	  diploid	  (2n).	  This	  indicates	  cells	  in	  G0	  and	  G1	  phases	  of	  the	  cell	  cycle.	  The	  higher	  intensity	  peaks	  represent	  the	  period	  of	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the	   cell	   cycle	   during	  which	   the	   cell	   is	   tetraploid.	  This	   occurs	  during	   the	  G2	   and	  M	  phases	   of	   the	   cell	   cycle.	   The	   portion	   of	   the	   plot	   below	   the	   non-­‐zero	   connecting	  baseline	  represents	  cells	  with	  DNA	  content	  between	  diploid	  and	  tetraploid,	  during	  the	  S	  phase.	  	  	  
	  
Figure	  7.11	  Flow	  cytometry	  results	  
for	  19%	  O2	  cells,	  without	  FGF2,	  
(control)	  at	  Passage	  21.	  
	  
Figure	  7.12	  Flow	  cytometry	  results	  
for	  19%	  O2	  cells,	  with	  FGF2,	  at	  
Passage	  22.	  
	  
Figure	  7.13	  Flow	  cytometry	  results	  
for	  5%	  O2	  cells,	  without	  FGF2,	  at	  
Passage	  21.	  
	  
Figure	  7.14	  Flow	  cytometry	  results	  
for	  5%	  O2	  cells,	  with	  FGF2,	  at	  
Passage	  22.
All	  four	  cell	  populations	  appear	  to	  have	  similar	  distributions	  of	  cells	  in	  each	  portion	  of	  the	  cell	  cycle	  (Figure	  7.11,	  Figure	  7.,	  Figure	  7.13,	  and	  Figure	  7.14).	  The	  majority	  of	  cells	  appear	  to	  be	  in	  the	  G0	  or	  G1	  phases,	  with	  limited	  numbers	  in	  the	  S	  phase,	  and	  an	  intermediate	  amount	  of	  cells	  in	  the	  G2	  or	  M	  phases.	  At	  the	  time	  the	  cells	  were	  fixed	  in	  preparation	  for	  performing	  flow	  cytometry,	  the	  cells	  had	  undergone	  the	  following	  numbers	  of	  population	  doublings:	  19%	  O2	  without	  FGF2,	  34.28;	  19%	  O2	  with	  FGF2,	  41.09;	  5%	  O2	  without	  FGF2,	  29.08;	  5%	  O2	  with	  FGF2,	  36.08.	  The	  populations	  likely	  have	  not	  yet	  undergone	  senescence	  and,	  therefore,	  appear	  similar	  to	  each	  other.	  
8 Discussion	  
	  The	  addition	  of	  FGF2	  and	  use	  of	   low	  oxygen	  concentration	  during	  culturing	  allows	  fibroblasts	  to	  undergo	  more	  population	  doublings	  in	  a	  shorter	  period	  of	  time	  before	  senescence	  than	  untreated	  fibroblasts	  in	  higher	  oxygen	  concentrations	  (Figure	  7.1).	  p53	   and	   p21	   accumulate	   at	   the	   mRNA	   level	   in	   older,	   untreated	   cell	   populations.	  Growth	  at	   lower	  oxygen	  concentrations	  appears	  to	  maintain	  lower	  levels	  of	  mRNA	  for	  p53	  and	  p21	  and	  protein	  for	  p53	  (Figure	  7.3	  and	  Figure	  7.4).	  This	  may	  be	  related	  to	  the	  mechanism	  by	  which	  iRC	  cells	  postpone	  senescence.	  While	  p53	  accumulates	  over	   time,	   it	   appears	   that	   it	  may	   be	   downregulated	   in	   later	   passage	   cells	   (Figure	  7.3).	  p53	  and	  p21	  show	  similar	  trends	  in	  all	  cell	  populations,	  which	  is	  indicative	  of	  p21’s	  downstream	  position	  in	  the	  p53	  senescence	  pathway	  and	  suggests	  that	  p53	  is	  active	  in	  all	  four	  cell	  populations	  (Figure	  7.3	  and	  Figure	  7.4).	  p16	  and	  MDM2	  do	  not	  exhibit	  similar	  trends	  to	  either	  p53	  or	  p21	  (Figure	  7.5	  and	  Figure	  7.6).	  MDM2	  was	  not	   expected	   to	   follow	   the	   same	   trends	   as	   p53	   because	   of	   its	   autoregulatory	  interaction	   with	   p53.	   This	   is	   also	   an	   illustration	   of	   p53’s	   ability	   to	   differentially	  activate	   its	   transcriptional	   targets.	  p16	  was	   tested	   for	  comparison	  of	   the	  effects	  of	  FGF2	   and	   of	   lower	   oxygen	   concentration	   on	   p53	   and	   an	   off-­‐target	   senescence	  pathway.	   The	   difference	   in	   p16	   and	   p53	   transcript	   levels	   suggests	   that	   the	  differences	   observed	   in	   the	   different	   treatments	   were	   related	   to	   p53	   and	   not	  reflected	  in	  all	  senescence	  pathways	  in	  the	  cells.	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  The	   protein	   experiments	   reflect	   the	   results	   of	   the	   RNA	   investigations	   (Figure	   7.3,	  Figure	  7.9,	  and	  Figure	  7.10).	  The	  trends	  observed	  in	  each	  of	  the	  populations	  at	  the	  transcript	   level	   are	   similar	   to	   those	   shown	   in	   the	  Western	   blots	   and	   subsequent	  quantification.	  From	  these	  results,	   it	   can	  be	  concluded	  that	   the	  differences	  seen	   in	  p53	  are	  likely	  due	  to	  transcriptional	  or	  post-­‐transcriptional	  regulation	  mechanisms.	  Both	  FGF2	  and	  lower	  oxygen	  concentration	  appear	  to	  have	  regulatory	  effects	  on	  p53	  prior	  to	  production	  of	  the	  protein.	  	  	  From	   the	   evidence	   gathered,	   it	   appears	   that	   supplementation	  of	  media	  with	  FGF2	  lowers	  p53	   levels.	  The	   same	  appears	   to	  be	   true	  of	   culturing	   cells	   at	   lower	  oxygen	  concentrations.	   Indirect	   lines	   in	   the	  network	  shown	  below	   indicate	   these	   findings.	  Direct	  lines	  show	  known	  interactions	  with	  p53	  (Figure	  8.1).	  	  	  
	  
Figure	  8.1	  A	  schematic	  of	  proposed	  p53	  interactions	  with	  studied	  proteins	  and	  
under	  low	  oxygen	  and	  FGF2.	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The	  experiments	  should	  be	  repeated,	  since	  this	  study	  only	  investigated	  these	  events	  once	  (n=1).	  Future	  studies	  should	  also	  include	  a	  longer	  time	  course	  for	  treatment	  of	  samples	  with	  FGF2	  and	  low	  oxygen	  and	  additional	  biological	  replicates	  so	  statistical	  significance	  of	  the	  observed	  changes	  can	  be	  determined.	  The	  results	  of	  the	  RT-­‐PCR,	  qRT-­‐PCR,	  and	  protein	  studies	  are	  interesting,	  even	  before	  the	  expected	  senescence	  point	   of	   untreated	   fibroblasts,	   but	   the	   story	   would	   be	   more	   complete	   with	   the	  addition	  of	  later	  time	  points	  beyond	  the	  senescence	  point	  of	  untreated	  cells.	  Future	  projects	   could	   also	   include	   studies	   of	   localization	   of	   p53	   transcripts	   or	   seek	   to	  identify	  possible	  additional	  post-­‐translational	  modifications	  of	  p53.	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